Table 1 Baseline clinical characteristics in subgroups from immunotherapy-naïve AChR subtype gMG patients
From: Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis
Baseline clinical characteristics | Subgroup 1 | Subgroup 2 | Subgroup 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
MGFA II | MGFA III/IV | P sig | Early-onset | Late-onset | P sig | Short duration | Long duration | P sig | |
(n = 100) | (n = 52) | (n = 91) | (n = 61) | (n = 76) | (n = 76) | ||||
Age, median (IQR), years | 48.5 (35.3–63) | 37 (30–49) | 0.005** | 35 (29–40) | 62.5 (56–66) |  < 0.001*** | 44 (32.5–60.8) | 42 (33–59.5) | 0.675 |
Gender, No. (%) | Â | Â | 1 | Â | Â | 0.136 | Â | Â | 0.105 |
 Male | 50 (50) | 26 (50) |  | 41 (45.1) | 35 (57.4) |  | 43 (56.6) | 33 (43.4) |  |
 Female | 50 (50) | 26 (50) |  | 50 (54.9) | 26 (42.6) |  | 33 (43.4) | 43 (56.6) |  |
Osserman Class at first sampling No. (%) |  |  |  < 0.001*** |  |  | 0.645 |  |  | 0.274 |
 IIa | 98 (98) | 29 (55.8) |  | 75 (82.4) | 52 (85.2) |  | 66 (86.8) | 61 (80.3) |  |
 IIb | 2 (2) | 23 (44.2) |  | 16 (17.6) | 9 (14.8) |  | 10 (13.2) | 15 (19.7) |  |
MGFA at first sampling No. (%) |  |  |  < 0.001*** |  |  | 0.017* |  |  | 0.322 |
 IIa | 46 (46) | 0 (0) |  | 22 (24.2) | 24 (39.3) |  | 28 (36.8) | 18 (23.7) |  |
 IIb | 54 (54) | 0 (0) |  | 29 (31.8) | 25 (41.0) |  | 28 (36.8) | 26 (34.2) |  |
 IIIa | 0 (0) | 25 (48.1) |  | 21 (23.1) | 4 (6.6) |  | 9 (11.8) | 16 (21.1) |  |
 IIIb | 0 (0) | 21 (40.4) |  | 13 (14.3) | 8 (13.1) |  | 9 (11.8) | 12 (15.8) |  |
 IVa | 0 (0) | 5 (9.6) |  | 5 (5.5) | 0 (0) |  | 2 (2.6) | 3 (3.9) |  |
 IVb | 0 (0) | 1 (1.9) |  | 1 (1.1) | 0 (0) |  | 0 (0) | 1 (1.3) |  |
AChR-Ab titer, median (IQR), nmol/L | 6.2 (2.7–9.5) | 5.4 (1.8–10.5) | 0.645 | 4.9 (1.8–9.4) | 6.9 (3.5–10.3) | 0.089 | 4.5 (1.9–9.5) | 6.4 (2.8–10.3) | 0.262 |
Thymoma, n (%) | 8 (8) | 7 (13.5) | 0.284 | 8 (8.8) | 7 (11.5) | 0.587 | 13 (17.1) | 2 (2.6) | 0.003** |
Disease course, median (IQR), months | 5 (2–16.3) | 11 (3.3–59.8) | 0.008** | 7 (3–20) | 5 (3–29) | 0.577 | 3 (2–4) | 27 (11–61) |  < 0.001*** |